Free shipping on all orders over $ 500

 About 8 results found for searched term "LB-100" (0.126 seconds)

Cat.No.  Name Target
M3013 SKLB1002 VEGFR/PDGFR
SKLB1002 is a potent and ATP-competitive VEGFR2 inhibitor with IC50 of 32 nM.
M8990 LB-100 PPAR
CAS# 1632032-53-1
LB-100 is a water soluble protein phosphatase 2A (PP2A) inhibitor, with IC50 of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells.
M10433 Bozitinib (PLB-1001) c-Met
CBT-101; APL-101; CBI-3103
Bozitinib (PLB-1001; CBT-101) is a highly selective, blood-brain barrier permeable c-MET kinase inhibitor.
M8208 4-Phenylbutyryl hydroxamic acid Others
4-Phenylbutyryl hydroxamic acid is a cell permeable HDAC inhibitor which is about 100 times more potent than parent carboxylic acid among nine HDAC enzymes.
M20637 SKLB-23bb HDAC
SKLB-23bb is an orally bioavailable HDAC6-selective inhibitor with IC50 values under 100 nmol/L, against most of the cell lines checked. It also has microtubule-disrupting ability.
M21001 Glycerol phenylbutyrate Others
GT4P, HPN-100M, Ravicti
Glycerol phenylbutyrate (GT4P, HPN-100M, Ravicti) is a nitrogen-binding agent and acts as a sigma-2 (σ2) receptor ligand with a pKi of 8.02. Glycerol phenylbutyrate is a prodrug in which phenylbutyrate (PBA) is released from the glycerol backbone by lipases in the gastrointestinal tract.
M30695 CMP8  Estrogen Receptor
CMP8, a selective ligand for estrogen receptor, binds to the mutant estrogen receptor ligand binding domain (ERLBD). CMP8 exhibits IC50 values of 29 nM , 41 nM, 1100 nM and 2200 nM for MGERα, MGRERα, hERα and hERβ, respectively.
M38634 10-​Isobutyryloxy-​8,​9-​epoxythymol isobutyrate Antibiotic
10-Isobutyryloxy-8,9-epoxythymol isobutyrate shows moderate antimicrobial activity against Staphylococcus aureus FDA 209 P, Staphylococcus aureus, Enterococcus faecalis, Candida albicans and Pseudomonas aeruginosa with MICs of 50, 250, 250, 250, and 1000 μg/mL, respectively.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.